2-year RESOLUTE data emphasise need for secondary prevention

The RESOLUTE All Comers trial showed that the Resolute zotarolimus-eluting stent was non-inferior to the Xience V everolimus eluting stent in terms of target lesion failure (revascularisation, myocardial infarction, or cardiac death). ¬†However, long-term follow-up data from drug-eluting stent trials are generally scarce. ¬†Silber et al. report the 2-year clinical outcomes from the original RESOLUTE […]

Read More…